Mar 03, 2020 / 02:20PM GMT
Chris Shibutani - Cowen and Company, LLC, Research Division - MD & Senior Research Analyst
(technical difficulty)
Chris Shibutani. I'm a member of the Cowen biotech team. We are thrilled to once again have Nektar Therapeutics join us at our 40th Annual Cowen Healthcare Conference.
Nektar has always been about some really potent core capabilities, technology and capabilities that have really been applied in some of the toughest challenges. Not everything always works. But I think, particularly from the standpoint of being able to establish a commercial business, these guys PEGylate stuff like nobody's business. I think they have tried to take on some of the most important challenges, and there have been sometimes bumps in the road, but now there's a deep commitment and a deepening layer of science to everything that they do. And with that, they're targeting areas in oncology, autoimmune disease. And these are never 4- to 7-quarter journeys. They're 4- to 7-year journeys. And the good news is we're quite a few years into those journeys. So I think this is a particularly opportune time
Nektar Therapeutics at Cowen HealthCare Conference Transcript
Mar 05, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers